[A21-29] Selpercatinib (RET fusion-positive thyroid cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 15.06.2021
Project no.: A21-29
Commission: Commission awarded on 15.03.2021 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Adults with advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib
Differentiated (papillary or follicular) thyroid cancer: added benefit not proven.
Anaplastic thyroid cancer: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.